|
|
|
On this week's episode of the Business of Biotech, Sean Kelley, Vice President for neuroscience and toxins, Portfolio Strategy and Program Leadership at AbbVie, talks through the development factors that determine whether a promising discovery becomes a medicine that reaches patients. |
|
|
|
|
|
|
|
|
|
|
| Connect With Life Science Leader: |
|
|
|